GSK’s two-drug HIV treatment clears key clinical assessments
Date: 2018-07-26   Author: Saif Ali Bepari  Category: #news

GSK’s two-drug HIV treatment clears key clinical assessments

GlaxoSmithKline, a British pharmaceutical company, has announced through clinical study results that their two-drug HIV treatment works just as well as the conventional triple therapy, even for individuals with comparatively high levels of the virus causing AIDS.

Investors and doctors alike had been anxious to see how 3TC, also known as the experimental combination of lamivudine and dolutegravir, measures up to highly potent triple drugs marketed by GSK’s rival Gilead Sciences.

As per reliable sources, ViiV Healthcare unit has developed the latest treatment. The company, in which GSK has a majority stake, had announced successful results from the two supposed GEMINI studies in the previous month.  However, the details of the study were not divulged until the International AIDS Conference was held in Amsterdam, wherein the unveiling took place.

An expert HIV researcher from Argentina, Pedro Cahn who piloted the GEMINI studies stated that the outcome showed the two-drug treatment to be as effective as the three-drug therapy. After monitoring 1400 patients over a span of 48 weeks, researchers discovered that 91% of the individuals taking lamivudine and dolutegravir showed high levels of viral control when compared with 93% of the individuals on the three-drug course – a negligible statistical gap.

Inability in controlling HIV, or virologic failure rates were steady and did not cross the 1% mark across all groups with none of the patients developing drug resistance, cite sources.

Cahn stated that this is a new treatment option and that the primary motivation of developing this course of treatment was to minimize the burden of the quantity of drugs patients had to ingest when on a life-long treatment plan.

GSK is anticipating that the shift toward two-drug course rather than the three-drug regimen will catapult its sales as it is offering treatment with fewer toxic side-effects. The company also points out that the two-drug course would be more affordable as lamivudine is out of patent restrictions.



About Author


Saif Ali Bepari

Saif Ali Bepari

Saif currently works as a content writer at Algosonline. A Computer Science graduate who has a zest for writing over coding, commenced his journey in the writing industry as a freelancer. Having had a prior freelance experience, he has tinkered with creative writing, ...

Read More

More from Saif


Post Recommendents

Building Energy Management Software Market Size, Analytical Overview, Growth Factors, Demand and Trends Forecast to 2024
Author: Partha Ray

The ' Building Energy Management Software market' study added by Market Study Report, LLC, enumerates an in-depth analysis of the powerful trends prevailing in the industry. This study also encompasses valuable information relating to the profitab...


Smart Building Automation Technologies Market Size Analytical Overview, Growth Factors, Demand and Trends Forecast to 2024
Author: Partha Ray

In its latest report on ' Smart Building Automation Technologies Market', Market Study Report, LLC, provides a concise analysis on the recent market trends. The report further includes statistics, market forecasts and revenue estimations, that in ...


Ambulatory Surgery Center Software System Market Size, Growth, Analysis, Outlook by 2019 - Trends, Opportunities and Forecast to 2024
Author: Partha Ray

Global Population Health Management Systems Market Size 2018-2023 report provide emerging opportunities in the market and the future impact of major Key vendors and Market driver and, support decisions in making cost-effective business decisions. ...